. 2023 Oct 19;66(21):14853–14865. doi: 10.1021/acs.jmedchem.3c01415

Table 2. OTR, V_1aR, and V_1bR Potencies (EC₅₀) and Efficacies (E_max) of OT and VP and 8–14^a.

	OTR				V_1aR			V_1bR
	EC₅₀ ± SEM [nM]	E_max ± SEM [%]	E/Z ratio EC₅₀		EC₅₀ ± SEM [nM]	E_max ± SEM [%]	E/Z ratio EC₅₀	EC₅₀ ± SEM [nM]	E_max ± SEM [%]	E/Z ratio EC₅₀
OT	2.46 ± 0.58	100		VP	0.64 ± 0.09	100		3.33 ± 0.48	100
E-8	4501 ± 1014	45 ± 3	1.3	E-12	722 ± 53	104 ± 1	2.0	107 ± 13	95 ± 1	5.3
Z-8	3496 ± 1887	35 ± 1	1.3	Z-12	1439 ± 108	99 ± 1	2.0	20.2 ± 6	95 ± 1	5.3
E-9	346 ± 30	89 ± 1	2.5	E-13	>10 μM			11,260 ± 1829	45 ± 3	1.6
Z-9	136 ± 6	90 ± 1	2.5	Z-13	>10 μM			7228 ± 1575	52 ± 5	1.6
E-10	94.6 ± 19	80 ± 1	3.1	E-14	>10 μM			4967 ± 754	48 ± 2	2.1
Z-10	30.7 ± 4	92 ± 0	3.1	Z-14	>10 μM			2373 ± 607	67 ± 2	2.1
E-11	263 ± 21	75 ± 1	2.0
Z-11	134 ± 17	86 ± 1	2.0

Determined in an IP-One accumulation assay performed with stable HEK293 cell lines expressing hOTR, hV_1aR, and hV_1bR. Efficacies were determined relative to the effect of OT (OTR) and VP (VPRs). Data represent mean values from at least three independent experiments performed in triplicate [standard error of the mean (SEM)].

Table 2. OTR, V1aR, and V1bR Potencies (EC50) and Efficacies (Emax) of OT and VP and 8–14a.

Table 2. OTR, V_1aR, and V_1bR Potencies (EC₅₀) and Efficacies (E_max) of OT and VP and 8–14^a.